Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.8.4699

Limited Diagnostic Value of microRNAs for Detecting Colorectal Cancer: A Meta-analysis  

Zhou, Xuan-Jun (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Dong, Zhao-Gang (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Yang, Yong-Mei (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Du, Lu-Tao (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Zhang, Xin (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Wang, Chuan-Xin (Department of Clinical Laboratory, Qilu Hospital, Shandong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.8, 2013 , pp. 4699-4704 More about this Journal
Abstract
Background: MicroRNAs have been demonstrated to play important roles in the development and progression of colorectal cancer. Several studies utilizing microRNAs as diagnostic biomarkers for colorectal cancer (CRC) have been reported. The aim of this meta-analysis was to comprehensively and quantitatively summarize the diagnostic value of microRNAs for detecting colorectal cancer. Methods: We searched PubMed, Embase and Cochrane Library for published studies that used microRNAs as biomarkers for the diagnosis of colorectal cancer. Summary estimates for sensitivity, specificity and other measures of accuracy of microRNAs in the diagnosis of colorectal cancer were calculated using the bivariate random effects model. A summary receiver operating characteristic (SROC) curve was also generated to summarize the overall effectiveness of the test. Result: Thirteen studies from twelve published articles met the inclusion criteria and were included. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odd ratio of microRNAs for the diagnosis of colorectal cancer were 0.81 (95%CI: 0.79-0.84), 0.78 (95%CI: 0.75-0.82), 4.14 (95%CI: 2.90-5.92), 0.24 (95%CI: 0.19-0.30), and 19.2 (95%CI: 11.7-31.5), respectively. The area under the SROC curve was 0.89. Conclusions: The current evidence suggests that the microRNAs test might not be used alone as a screening tool for CRC. Combining microRNAs testing with other conventional tests such as FOBT may improve the diagnostic accuracy for detecting CRC.
Keywords
Colorectal cancer; microRNAs; diagnostic; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al (2011). Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol, 46, 1391-402.   DOI   ScienceOn
2 Kanaan Z, Rai SN, Eichenberger MR, et al (2012). Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg, 256, 544-51.   DOI
3 Koga Y, Yasunaga M, Takahashi A, et al (2010). MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila), 3, 1435-42.   DOI   ScienceOn
4 Collins JF, Lieberman DA, Durbin TE, et al (2005). Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med, 142, 81-5.   DOI   ScienceOn
5 Corte H, Manceau G, Blons H, et al (2012). MicroRNA and colorectal cancer. Dig Liver Dis, 44, 195-200.   DOI   ScienceOn
6 Wang S, Wang L, Bayaxi N, et al (2013a). A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut, 62, 280-9.   DOI   ScienceOn
7 Wang S, Xiang J, Li Z, et al (2013b). A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer.
8 Whiting P, Rutjes AW, Reitsma JB, et al (2003). The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25.   DOI   ScienceOn
9 Whiting P, Rutjes AW, Reitsma JB, et al (2004). Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med, 140, 189-202.   DOI   ScienceOn
10 Wu CW, Ng SS, Dong YJ, et al (2012). Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut, 61, 739-45.   DOI   ScienceOn
11 Zhang B, Pan X, Cobb GP, et al (2007). MicroRNAs as oncogenes and tumor suppressors. Dev Biol, 302, 1-12.   DOI   ScienceOn
12 Zhou T, Zhang G, Liu Z, et al (2013). Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis, 28, 19-24.   DOI   ScienceOn
13 Liu K, Li G, Fan C, et al (2011). Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J Int Med Res, 39, 2288-95.   DOI
14 Mandel JS (2008). Screening for colorectal cancer. Gastroenterol Clin North Am, 37, 97-115, vii.   DOI   ScienceOn
15 Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105, 10513-8.   DOI   ScienceOn
16 Reitsma JB, Glas AS, Rutjes AW, et al (2005). Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol, 58, 982-90.   DOI   ScienceOn
17 Ng EK, Chong WW, Jin H, et al (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut, 58, 1375-81.   DOI   ScienceOn
18 O’Connell JB, Maggard MA, Ko CY (2004). Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst, 96, 1420-5.   DOI   ScienceOn
19 Pu XX, Huang GL, Guo HQ, et al (2010). Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol, 25, 1674-80.   DOI   ScienceOn
20 Schetter AJ, Leung SY, Sohn JJ, et al (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-36.
21 Schetter AJ, Nguyen GH, Bowman ED, et al (2009). Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res, 15, 5878-87.   DOI   ScienceOn
22 Wang B, Zhang Q (2012). The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol, 138, 1659-66.   DOI   ScienceOn
23 Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al (2010). Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med, 153, 368-77.   DOI   ScienceOn
24 Deville WL, Buntinx F, Bouter LM, et al (2002). Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol, 2, 9.   DOI
25 Levin B, Lieberman DA, McFarland B, et al (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin, 58, 130-60.   DOI   ScienceOn
26 Wang Q, Huang Z, Ni S, et al (2012). Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One, 7, e44398.   DOI
27 Deeks JJ, Macaskill P, Irwig L (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 58, 882-93.   DOI   ScienceOn
28 Gallagher EJ. (1998). Clinical utility of likelihood ratios. Ann Emerg Med, 31, 391-7.   DOI   ScienceOn
29 Giraldez MD, Lozano JJ, Ramirez G, et al (2013). Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol, 11, 681-8 e3.   DOI   ScienceOn
30 Glas AS, Lijmer JG, Prins MH, et al (2003). The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol, 56, 1129-35.   DOI   ScienceOn
31 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
32 Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.   DOI   ScienceOn
33 Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.   DOI